Kaleido Biosciences (KLDO) Stock Overview
A clinical-stage healthcare company, develops microbiome metabolic therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
KLDO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Kaleido Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.35 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 9,900.00% |
| 1 Year Change | 0% |
| 3 Year Change | -50.00% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Shareholder Returns
| KLDO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -0.6% |
| 1Y | 0% | 25.5% | 21.7% |
Return vs Industry: KLDO underperformed the US Pharmaceuticals industry which returned 24.2% over the past year.
Return vs Market: KLDO underperformed the US Market which returned 21.3% over the past year.
Price Volatility
| KLDO volatility | |
|---|---|
| KLDO Average Weekly Movement | 7,969.4% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KLDO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KLDO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | kaleido.com |
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology.
Kaleido Biosciences, Inc. Fundamentals Summary
| KLDO fundamental statistics | |
|---|---|
| Market cap | US$4.26k |
| Earnings (TTM) | -US$90.29m |
| Revenue (TTM) | US$1.10m |
Is KLDO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KLDO income statement (TTM) | |
|---|---|
| Revenue | US$1.10m |
| Cost of Revenue | US$67.80m |
| Gross Profit | -US$66.70m |
| Other Expenses | US$23.59m |
| Earnings | -US$90.29m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did KLDO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/10 13:40 |
| End of Day Share Price | 2026/03/10 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kaleido Biosciences, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Taylor Feehley | Chardan Capital Markets, LLC |
| Keay Nakae | Chardan Capital Markets, LLC |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |